# AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT

> **NCT07467252** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ministry of Health, Saudi Arabia** · enrollment: 200 (estimated)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Pyrazinamide and Hydroxychloroquine (AI-Optimised)
- **DRUG:** Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)

## Key facts

- **NCT ID:** NCT07467252
- **Lead sponsor:** Ministry of Health, Saudi Arabia
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07467252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07467252, "AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07467252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*